VIVS VivoSim Labs, Inc.

$VIVS Company already announced no reverse split coming. But believe people are using reverse split senario to push price down. Expect to start reversing to upside in next month.

$VIVS I lost half of my money. What the hell. I lost $7K I should have bought Pokémon cards instead. What a joke!!! I was very bullish now I am pissed.

$VIVS hey Lilly she trades .22 now on that 90% liver so instead of investing, how about you reaching into one of your wealthy pockets and just buy them out right then 

Yesterday's Recap: $VIVS Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026 $ANY Completes Rebrand as DarkHorse Technologies Inc. $CBDW Signs LOI for Potential Transaction Involving Texas Power Plant and Data Center Project $GMGMF Gen 2.0 Graphene Manufacturing Plant

$VIVS Lowered my average for the 8th time since my entry in 2016. Now down to $7.50 from $14. Tiny sum though, so its easy.

$VIVS they just dipped her .26 on decent news….. added Long term account as we wait. Nice volume PM

$VIVS What the hell !!!! At this rate, by the end of the month this GARBAGE is going to .10 cents. I’m so PISSED. I use to be bullish now screw this stock!!

$VIVS Did they burn thru Lilly money - had to kick in ATM? Months since any news - as long as CEO and Execs are receiving pay checks - no need to defend stock or inform retail sheep.

$VIVS This is scam company... Dilution machine , CEO of 10 people paid 1 million... Who is dumb enough to know the story.. They post fake news , big pump , hedge fund do naked short and then buy the dillution the next day to cover... Total scam... Same thing in few months

$VIVS VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

$VIVS At least nothing than more possible ATM sales at bargain basement prices - smells like desperation time - maybe Ms Lilly can come to rescue again - recycling weeks old data as a press release smells like rotten food.

$VIVS Probably used up that last milestone payment - are they flooding with an ATM or just fat and happy cashing pay checks?

$VIVS VivoSim Labs Expands Asia-Pacific Access Key Partnership Details South Korea Partner: JCBio was appointed as an authorized distributor to bring human-based toxicology platforms to the Korean market. Core Offering: The distribution covers NAMKind toxicology services focusing on the human liver and small intestine. How the Platform Works Model: Uses a "molecules in, data out" framework. Speed: Targets a 30-day turnaround time per test compound. Goal: Helps pharmaceutical developers spot toxicity issues early without relying solely on animal testing. Why the APAC Market Matters South Korea: Local regulators (MFDS) are increasingly aligning with U.S. FDA standards to accept non-animal New Approach Methodologies (NAMs).

$VIVS Commercial Sales Overview Secured via local Chinese distributor Tekon. Represents a meaningful share of contracted revenue. Validates company channel strategy in Asia-Pacific.📌 Engagement Details Gastrointestinal toxicology screening services. NAMkind GI efficacy profiling. Targeting oncology and other disease candidates.📈 Market Opportunity China addressable market valued at $2 billion. Growing at a 10% compound annual growth rate. Backed by broader regulatory shifts away from animal testing

$VIVS Commercial Sales Overview Secured via local Chinese distributor Tekon. Represents a meaningful share of contracted revenue. Validates company channel strategy in Asia-Pacific.📌 Engagement Details Gastrointestinal toxicology screening services. NAMkind GI efficacy profiling. Targeting oncology and other disease candidates.📈 Market Opportunity China addressable market valued at $2 billion. Growing at a 10% compound annual growth rate. Backed by broader regulatory shifts away from animal testing.

$VIVS Today's news is neutral to slightly positive and should not affect the stock price significantly. The stock is down right now because traders who bought high in premarket are trying to exit. Last offering was at $0.85 per share in July. On August 31, their Chief Commercial Officer purchase 10,000 shares at $0.2804 per share. Armistice Capital owns 10.47%. They have a reasonable cash runway. They may receive up to $45 million in future commercial milestone payments from Eli Lilly related to the sale of their inflammatory bowel disease drug program. The company market cap ($4.3 million on my broker) is well below potential receipts from Eli Lilly. They may announce new commerical contracts at any time, especially in 2027. They recently added two customers in China. I'm not particularly excited about their business model, hard to know when they will be profitable. Seems like their services are too cheap.

$VIVS this technology has real value imo, sparing animals from needless suffering and reducing risk from new medicines.

$VIVS someone desperately trying to keep this locked down here….. bring the buying pressure!!

$VIVS WTF!! I’m losing 55% now . Last week it was 50% at a $7000 now I am losing $7800 now. What a joke. I looks like this stock loses 5% a week. What a POS. I feel like selling now. This is like a sick science experiment where I am the victim. I am afraid if I do sell this it will skyrocket the next day. I am so confused!!!

$VIVS welp, so far almost everyone here has been trying to pump this and say how it's going to moon, and so far it's a real dud. I think the naysayers are right and you are all hoping to just get back a little from buying in so high and holding.